戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 onse observed at 4 h with 100 nM des-Arg(10)-kallidin.
2 he B1 receptor antagonist des-Arg(10),Leu(9)-kallidin.
3 nse observed at 20 h with 100 nM des-Arg(10)-kallidin.
4 inding of the B1-selective agonist des-Arg10-kallidin.
5  subtype-selective agonists BK and des-Arg10-kallidin.
6 naling by B2 receptor agonists bradykinin or kallidin.
7 gonists des-Arg(9)-bradykinin or des-Arg(10)-kallidin.
8                              Both desArg(10)-kallidin and ACE inhibitors enhance arginine uptake and
9 ation of their respective ligands, des-Arg10-kallidin and bradykinin (BK), both wild type receptors,
10 HEK293 cells using the agonist [3H]des-Arg10-kallidin and the antagonist [3H]NPC17731.
11 Ca(2+) exchanger is required for des-Arg(10)-kallidin- and TGF-beta1-stimulated fibrogenesis and part
12     IDE specifically degrades bradykinin and kallidin at the Pro/Phe site.
13 of B1R signaling to its agonist, des-Arg(10)-kallidin (DAKD).
14 -known BR ligands, BK, [des-Arg(10), Leu(9)]-kallidin (DALKD), and HOE140 showed different binding pr
15 luated the feasibility of using radiolabeled kallidin derivatives to visualize B1R expression in a pr
16               In addition, unlike desArg(10)-kallidin, enalaprilat can also release NO independent of
17                                   DesArg(10)-kallidin enhances inositol-phosphate generation and elev
18 ever, nardilysin does not release desArg(10) kallidin from the physiological precursor low molecular
19 nalaprilat and the peptide ligand desArg(10)-kallidin (in nanomolar concentrations) release NO by act
20 ition, B1 receptor activation by des-Arg(10)-kallidin induced a rise in cytosolic Ca(2+) that is cons
21  cycloheximide did not block the des-Arg(10)-kallidin-induced increase in CTGF mRNA.
22 d formation of bradykinin (BK) and Lys-BK or kallidin (KD) and their carboxypeptidase metabolites des
23 d endogenous BR ligands, bradykinin (BK) and kallidin (KD), this interaction could not be predicted,
24 LMKRPPGFSPFRSSRI-NH(2), releasing desArg(10) kallidin (KRPPGFSPF).
25                          Bradykinin (BK) and kallidin (Lys-BK), liberated from kininogens by kallikre
26 es at two monobasic sites M-K and F-R of the kallidin model peptide Abz-MISLMKRPPGFSPFRSSRI-NH(2), re
27 +)](i) in cells stimulated with B2R agonists kallidin or bradykinin.
28  of BK, a B2 receptor-selective peptide, and kallidin or Lys-BK, a less receptor-selective peptide, f
29 at radiolabeled peptides based on the native kallidin sequence were ineffective at visualizing B1R-po
30 inding of the less subtype-selective agonist kallidin showed little sensitivity to TM-VI exchange.
31 engagement of the B1 receptor by des-Arg(10)-kallidin stabilized connective tissue growth factor (CTG
32 ing growth factor (TGF)-beta and des-Arg(10)-kallidin stimulate the expression of connective tissue g
33 on of the kinin B1 receptor with des-Arg(10)-kallidin stimulated a rise in cytosolic Ca(2+) that was
34  with kinetics distinct from the des-Arg(10)-kallidin-stimulated Ca(2+) response.
35 RNA expression in TGF-beta1- and des-Arg(10)-kallidin-stimulated human lung myofibroblasts.
36        Our results show that the des-Arg(10)-kallidin-stimulated increase in alpha1(I) collagen mRNA
37                              The des-Arg(10)-kallidin-stimulated increase of cytosolic Ca(2+) was blo
38 vity, blocked the TGF-beta1- and des-Arg(10)-kallidin-stimulated increases of CTGF mRNA.
39              In contrast to BK and des-Arg10-kallidin, the binding of the less subtype-selective agon
40 via CPM-mediated conversion of bradykinin or kallidin to des-Arg kinin B1R agonists.
41 contrast, incubation of 3H-labeled des-Arg10-kallidin with cells expressing B1KR resulted in a modest

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。